Laurus Labs Limited – FDA 483, Jan 31, 2025

The Food and Drug Administration (FDA) conducted an inspection of Laurus Labs Limited, an Active Pharmaceutical Ingredient (API) manufacturer located in Anakapalli District, Andhra Pradesh, India, from January 27 to 31, 2025. The inspection resulted in a Form 483 observation, highlighting a significant deviation from established quality protocols. The primary issue identified was the company's failure to ensure that equipment qualification protocols were reviewed and approved by the quality unit. Specifically, FDA investigators observed that multiple pieces of manufacturing equipment, crucial for the production of various APIs, had been qualified and utilized without proper protocol approval from the quality control unit. This indicates a systemic weakness in the firm's quality management system, essential for maintaining product quality and safety. This observation is critical under current Good Manufacturing Practices (GMP), which mandate stringent controls over equipment qualification to ensure its suitability for intended use. Laurus Labs Limited is now expected to thoroughly investigate these deficiencies, implement comprehensive corrective and preventive actions, and submit a detailed response to the FDA outlining how these issues will be resolved to achieve and maintain compliance with regulatory standards.